biomarkers

Nirmidas Biotech raises $2M in seed round for fluorescent dye meant for diagnostics

Stanford University spinout Nirmidas Biotech has raised $2 million in seed funding to commercialize its fluorescence technology that enhances 100-fold a researcher’s ability to detect disease biomarkers, said the company’s R&D director Joshua Robinson. It’s meant to pick up the subtle traces found in blood from early-stage cancer or hard-to-read autoimmune disorders – conditions that typically use fluorescent dye tests. […]

By Meghana Keshavan

Devices & Diagnostics

Stanford spinoff goes data-mining for a better diagnostic for preeclampsia

Fans of the PBS series Downton Abbey were shocked when the character Lady Sybil died from eclampsia after giving birth last season. Sadly, the same condition still kills expectant and new mothers today, nearly 100 years later. Carmenta Bisocience was spun out of Stanford University last year to commercialize a better way for obstetricians to […]

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.

Devices & Diagnostics

Biomarker test could make screening for lung cancer cheap and easy

A straw, a bag and a microchip may be the future of lung cancer screening. A startup in Louisville, Kentucky, is working on a method that would make it easy enough and cheap enough to establish a national screening program. A patient breathes into the bag. The bag is sealed and sent to a lab. […]